Join our
Investor Newsletter

To receive Investor News as it is released please sign up

News Releases

Renalytix Convenes Expert Panel at VA Healthcare Summit

November 10, 2021
Leading clinicians discuss enabling long-term kidney health in Veterans with type 2 diabetes and early-stage chronic kidney disease NEW YORK and SALT LAKE CITY, Nov. 10, 2021 (GLOBE NEWSWIRE) -- In recognition of National Diabetes Month and concurrent with the launch of KidneyIntelX in the Veterans

Renalytix Reports Full Year Fiscal 2021 Results

October 21, 2021
LONDON and SALT LAKE CITY, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX), (LSE: RENX) an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based

Renalytix Appoints Daniel J. Levangie to its Board of Directors

August 30, 2021
Levangie brings extensive commercial operating experience to Renalytix, served on boards of Exact Sciences, Insulet Corporation and Hologic NEW YORK and SALT LAKE CITY, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Renalytix Plc (NASDAQ: RNLX) (LSE: RENX) today announced the appointment of Daniel J.
Displaying 1 - 10 of 73